Pfizer's fortunes overshadow first-quarter dealmaking

Pfizer accounted for almost a quarter of biopharma’s buyout spend last year, a contribution that looks set to grow considerably in 2023. This is thanks to the $45bn it has pledged to spend on Seagen – antitrust approval pending – in the sector’s biggest buyout since the Abbvie-Allergan deal in 2019.